NCT04306965View on ClinicalTrials.gov

Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

June 23, 2022

Study Completion Date

August 18, 2022

Conditions
Atopic Dermatitis
Interventions
DRUG

Apremilast

30 mg twice daily (BID)

Trial Locations (1)

02111

Tufts Medical Center, Department of Dermatology, Boston

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Tufts Medical Center

OTHER

NCT04306965 - Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab | Biotech Hunter | Biotech Hunter